History of cancer and atrial cardiopathy: A secondary analysis of the ARCADIA clinical trial Journal Article


Authors: Navi, B. B.; Elkind, M. S. V.; Zhang, C.; Tirschwell, D. L.; Kronmal, R. A.; Elm, J.; Broderick, J. P.; Gladstone, D. J.; Beyeler, M.; Kamel, H.; Longstreth, W. T.
Article Title: History of cancer and atrial cardiopathy: A secondary analysis of the ARCADIA clinical trial
Abstract: BACKGROUND: Approximately 50% of strokes in patients with cancer are classified as cryptogenic after standard evaluation. Atrial cardiopathy could explain some cancer-related cryptogenic strokes. However, the relationship between cancer and atrial cardiopathy is uncertain. METHODS AND RESULTS: We conducted a post hoc cross-sectional analysis of baseline data collected from participants enrolled in ARCADIA (Atrial Cardiopathy and Antithrombotic Drugs in Prevention After Cryptogenic Stroke), a clinical trial conducted from 2018 to 2023 at 185 sites. The analytical cohort presented herein included patients age ≥45 years with cryptogenic ischemic stroke within the past 180 days, of whom a subset had atrial cardiopathy and were randomized into the trial. Atrial fibrillation before enrollment was exclusionary. Linear regression models examined the associations between history of cancer and the atrial cardiopathy biomarkers analyzed in ARCADIA: serum NT-proBNP (N-terminal pro-B-type natriuretic peptide), P-wave terminal force in ECG lead V1, and left atrial diameter index on echocardiogram. Among 3745 patients with cryptogenic stroke, 506 (13.5%) had history of cancer. History of cancer was associated with higher median values of NT-proBNP (126 versus 103 pg/mL, P<0.001) and left atrial diameter index (1.9 versus 1.8 cm/m2, P<0.001) but similar median values of P-wave terminal force in ECG lead V1 (3000 versus 3025, P=0.08). After adjusting for demographics, tobacco use, and body mass index, no significant association remained between history of cancer and log-transformed NT-proBNP (standardized formula presented , -0.06 [95% CI, -0.15 to 0.02]), P-wave terminal force in ECG lead V1 (standardized formula presented , -0.02 [95% CI, -0.11 to 0.08]), or left atrial diameter index (standardized formula presented , 0.06 [95% CI, -0.05 to 0.16]). CONCLUSIONS: In a multicenter, prospective, cryptogenic stroke cohort, history of cancer was not associated with selected biomarkers for atrial cardiopathy. REGISTRATION: URL: https://www.ClinicalTrials.gov; Unique Identifier: NCT03192215.
Keywords: controlled study; aged; middle aged; clinical trial; pathophysiology; neoplasm; neoplasms; biomarkers; biological marker; heart disease; randomized controlled trial; risk factors; diagnostic imaging; risk factor; risk assessment; blood; multicenter study; diagnosis; peptide fragments; peptide fragment; cross-sectional study; cross-sectional studies; epidemiology; brain natriuretic peptide; fibrinolytic agent; fibrinolytic agents; prevention and control; heart diseases; etiology; complication; heart atrium; heart atria; ischemic stroke; natriuretic peptide, brain; cancer; humans; human; male; female; atrial cardiopathy; cryptogenic stroke; pro-brain natriuretic peptide (1-76)
Journal Title: Journal of the American Heart Association
Volume: 14
Issue: 9
ISSN: 2047-9980
Publisher: Wiley Blackwell  
Date Published: 2025-05-06
Start Page: e040543
Language: English
DOI: 10.1161/jaha.124.040543
PUBMED: 40265582
PROVIDER: scopus
DOI/URL:
Notes: Article -- MSK corresponding author is Babak Navi -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Babak Navi
    40 Navi